Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457345 | 0.89 | MAPK14 (0.43) | MAPK14BRAFPPARG | |
| SCHEMBL14490863 | 0.82 | MAPK14 (0.55) | MAPK14TRPA1MAPK8MAP4K4HSPB1 | |
| SCHEMBL14003196 | 0.81 | MAPK8 (0.59) | MAPK14MAPK8MAP4K4 | |
| SCHEMBL4849482 | 0.81 | TRPA1 (0.44) | MAPK14TRPA1GCKMAP4K4HSPB1 | |
| SCHEMBL4853710 | 0.81 | MAPK14 (0.47) | MAPK14BRAFTRPA1GCKMAPK8 | |
| SCHEMBL4860231 | 0.79 | SCN9A (0.46) | MAPK14BRAFTRPA1GCKMAPK8 | |
| SCHEMBL4858175 | 0.79 | MAPK14 (0.60) | MAPK14MAPK8MAP4K4 | |
| SCHEMBL14457338 | 0.78 | MAPK8 (0.52) | MAPK14MAPK8MAP4K4 | |
| SCHEMBL14003195 | 0.76 | MAPK8 (0.67) | MAPK14MAPK8MAP4K4 | |
| SCHEMBL4859569 | 0.73 | MAPK8 (0.69) | MAPK14MAPK8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK3 | MAPK14 12/4885BRAF 45/4885TRPA1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.